CAIRO: Sovaldi, both locally-made and imported, on patients with liver fibrosis has a 70 percent success rate in treating advanced cases of hepatitis C, compared to 90 percent of general cases, head of the National Committee for Control of Viral Hepatitis (NCCVH) Waheed Dous told Youm7.
The government has recently halted importing treatments, replacing them with locally-manufactured drugs. It announced it hopes to cure some 500,000 patients during 2016 using domestically produced regimens.
More than 30,000 patients have received the Egyptian Sovaldi at liver treatment centers, said Dous. The local version will be available at 900 EGP ($114) instead of 1,200 EGP at pharmacies.
NCCVH previously announced that around 157,000 patients have been treated using the Egyptian-made Sovaldi during 2015.
A member of NCCVH, Yehia Shazly, previously said that some 17,000 Sovaldi bottles remaining from the imported batches will be distributed among liver centers, and that 150,000 bottles of the locally-made Daklinza will be available at the centers by the end of January.
Having one of the highest infection rates of hepatitis C infection in the world, Egypt started in 2014 a treatment regimen based on imported medications that have proved a breakthrough in treating the virus.
Additional reporting by Waleed Abdel Salam.